189808-70-6

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl 2-2-[2-(2-aminoethoxy)ethoxy]ethoxyacetate is used as a building block for the synthesis of drug conjugates and prodrugs. The reactive amino group allows for the attachment of drug molecules, while the t-butyl protected carboxyl group can be deprotected under acidic conditions in the body, releasing the active drug.
Used in Bioconjugation:
In the field of bioconjugation, tert-butyl 2-2-[2-(2-aminoethoxy)ethoxy]ethoxyacetate is used as a linker molecule to attach biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The hydrophilic PEG spacer improves the stability and solubility of the conjugates, while the reactive amino group allows for the attachment of various functional groups.
Used in Drug Delivery Systems:
tert-butyl 2-2-[2-(2-aminoethoxy)ethoxy]ethoxyacetate is used as a component in the design of drug delivery systems, such as nanoparticles or hydrogels. The hydrophilic PEG spacer and the reactive amino group enable the incorporation of drug molecules and the formation of stable drug delivery systems with controlled release properties.
Used in Chemical Synthesis:
In chemical synthesis, tert-butyl 2-2-[2-(2-aminoethoxy)ethoxy]ethoxyacetate is used as an intermediate or a protecting group in the synthesis of various organic compounds. The t-butyl protected carboxyl group can be selectively deprotected under acidic conditions, allowing for the controlled synthesis of complex molecules.

Upstream product

• 139115-89-2 2-<2-<2-<(Methanesulfonyl)oxy>ethoxy>ethoxy>ethanol 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 603-35-0 triphenylphosphine 
• 5197-62-6 2-[2-(chloroethoxy)ethoxy]ethanol 
• 35059-50-8 t-butyl diazoacetate 
• 75001-08-0 2-{2-[2-(2-hydroxyethoxy)ethoxy]ethyl}isoindole-1,3-dione 
• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 518044-31-0 tert-butyl 2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)acetate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 172531-36-1 tert-butyl 2-[2-(2-(2-azidoethoxy)ethoxy)ethoxy]acetate 
• 6367-36-8 tert-butyl 2-azidoacetate 
• 77544-68-4 8-tosyloxy-3,6-dioxaoctanol 

Downstream Products

• 1351169-41-9 C₂₄H₃₈N₂O₇ 
• 1351169-40-8 2-[2-(2-{2-[(S)-2-((2S,3R)-3-{[(9H-fluoren-9-yl)methoxy]carbonyl amino}-2-hydroxy-4-phenylbutanamido)-4-methylpentanamido]ethoxy}ethoxy)ethoxy]acetic acid 
• 1351169-28-2 (S,E)-4-[3-(3,5-di-tert-butylphenyl)-3-oxoprop-1-enyl]-2-(3-{2-[2-(2-{2-[4-methyl-2-(4-phenylbutanamido)pentanamido]ethoxy}ethoxy)ethoxy]acetamido}propoxy)benzoic acid 

Relevant academic research and scientific papers

TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands

Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin ligase have emerged as a novel paradigm in drug development. Herein we found that linker attachment points of CRBN ligands highly affect their aqueous stability and neosubstrate degradation features. This work provides a blueprint for the assembly of future heterodimeric CRBN-based degraders with tailored properties.

Self-Adjuvanting Cancer Vaccines from Conjugation-Ready Lipid A Analogues and Synthetic Long Peptides

Self-adjuvanting vaccines, wherein an antigenic peptide is covalently bound to an immunostimulating agent, have been shown to be promising tools for immunotherapy. Synthetic Toll-like receptor (TLR) ligands are ideal adjuvants for covalent linking to peptides or proteins. We here introduce a conjugation-ready TLR4 ligand, CRX-527, a potent powerful lipid A analogue, in the generation of novel conjugate-vaccine modalities. Effective chemistry has been developed for the synthesis of the conjugation-ready ligand as well as the connection of it to the peptide antigen. Different linker systems and connection modes to a model peptide were explored, and in vitro evaluation of the conjugates showed them to be powerful immune-activating agents, significantly more effective than the separate components. Mounting the CRX-527 ligand at the N-terminus of the model peptide antigen delivered a vaccine modality that proved to be potent in activation of dendritic cells, in facilitating antigen presentation, and in initiating specific CD8+ T-cell-mediated killing of antigen-loaded target cells in vivo. Synthetic TLR4 ligands thus show great promise in potentiating the conjugate vaccine platform for application in cancer vaccination.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

ADJUVANT COMPOUNDS

Adjuvant compounds are described, as well as their conjugates comprising peptide antigens or other immunomodulatory moieties. Also described are methods of modulating immune responses in a subject in need thereof, as well as methods of treating cancer, viral or bacterial infections comprising administering the adjuvant compounds or the conjugates to a subject in need thereof.

RAS BINDING PEPTIDES AND METHODS OF USE

The present invention provides Ras modulators including inhibitors and/or antagonists of Ras, Ras binding, and Ras-dependent cell signaling activity. Also provided are methods of utilizing the Ras modulators as therapeutics.

Amide bond-containing monodisperse polyethylene glycols beyond 10000 da

Although monodisperse polyethylene glycols (M-PEGs) above 4000 Da are especially valuable in biomedical applications, their synthesis remains a long-standing challenge. To this end, a peptide-based strategy for such M-PEGs was developed. With macrocyclic sulfates as the key intermediates, a panel of oligoethylene glycol (OEG) containing ω-amino acids were prepared with high efficiency. Through solid phase peptide synthesis (SPPS), these amino acids were conveniently assembled into a series of amide bond-containing M-PEGs with high flexibility in molecular weight and amide density selection. With this strategy, an M-PEG of 10262 Da was prepared on a gram scale and its biocompatibility was assessed in a mice model.

Nanofibers and morphology shifting micelles

The invention discloses novel morphology shifting micelles and amphiphilic coated metal nanofibers. Methods of using and making the same are also disclosed.

Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimer's disease

In an effort to combat the multifaceted nature of Alzheimer's disease (AD) progression, a series of multifunctional, bivalent compounds containing curcumin and diosgenin were designed, synthesized, and biologically characterized. Screening results in MC65 neuroblastoma cells established that compound 38 with a spacer length of 17 atoms exhibited the highest protective potency with an EC50 of 111.7 ± 9.0 nM. A reduction in protective activity was observed as spacer length was increased up to 28 atoms and there is a clear structural preference for attachment to the methylene carbon between the two carbonyl moieties of curcumin. Further study suggested that antioxidative ability and inhibitory effects on amyloid-β oligomer (AβO) formation may contribute to the neuroprotective outcomes. Additionally, compound 38 was found to bind directly to Aβ, similar to curcumin, but did not form complexes with the common biometals Cu, Fe, and Zn. Altogether, these results give strong evidence to support the bivalent design strategy in developing novel compounds with multifunctional ability for the treatment of AD.